1
|
Liu X, Zhao Y, Liang X, Ding Y, Hu J, Deng N, Zhao Y, Huang P, Xie W. In Vivo Evaluation of Self-assembled nano-Saikosaponin-a for Epilepsy Treatment. Mol Biotechnol 2023:10.1007/s12033-023-00851-7. [PMID: 37608078 DOI: 10.1007/s12033-023-00851-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Accepted: 08/03/2023] [Indexed: 08/24/2023]
Abstract
Saikosaponin-a (SSa) exhibits antiepileptic effects. However, its poor water solubility and inability to pass through the blood-brain barrier greatly limit its clinical development and application. In this study, SSa-loaded Methoxy poly (ethylene glycol)-poly(ε-caprolactone) (MePEG-SSa-PCL) NPs were successfully prepared and characterized. Our objective was to further investigate the effect of this composite on acute seizure in mice. First, we confirmed the particle size and surface potential of the composite (51.00 ± 0.25 nm and - 33.77 ± 2.04 mV, respectively). Further, we compared the effects of various MePEG-SSa-PCL doses (low, medium, and high) with those of free SSa, valproic acid (VPA - positive control), and saline only (model group) on acute seizure using three different acute epilepsy mouse models. We observed that compared with the model group, the three MePEG-SSa-PCL treatments showed significantly lowered seizure frequency in mice belonging to the maximum electroconvulsive model group. In the pentylenetetrazol and kainic acid (KA) acute epilepsy models, MePEG-SSa-PCL increased both clonic and convulsion latency periods and shortened convulsion duration more effectively than equivalent SSa-only doses. Furthermore, hematoxylin-eosin and Nissl staining revealed considerably less neuronal damage in the hippocampal CA3 area of KA mice in the SSa, VPA, and three MePEG-SSa-PCL groups relative to mice in the model group. Hippocampal gamma-aminobutyric acid-A (GABA-A) receptor and cleaved caspase-3 expression levels in KA mice were significantly higher and lower, respectively, in the three MePEG-SSa-PCL treatment groups than in the model group. Thus, MePEG-SSa-PCL exhibited a more potent antiepileptic effect than SSa in acute mouse epilepsy models and could alleviate neuronal damage in the hippocampus following epileptic seizures, possibly via GABA-A receptor expression upregulation.
Collapse
Affiliation(s)
- Xueqi Liu
- Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
| | - Yunyan Zhao
- Department of Critical Care Medicine, The Afflliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Guangzhou, 510130, China
| | - Xiaoshan Liang
- Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
| | - Yuewen Ding
- Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
| | - Jiao Hu
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
| | - Ning Deng
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
| | - Yiting Zhao
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China
| | - Ping Huang
- Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - Wei Xie
- Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
| |
Collapse
|
2
|
Di Trani N, Racca N, Demarchi D, Grattoni A. Comprehensive Analysis of Electrostatic Gating in Nanofluidic Systems. ACS APPLIED MATERIALS & INTERFACES 2022; 14:35400-35408. [PMID: 35905377 DOI: 10.1021/acsami.2c08809] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Molecular transport in nanofluidic systems exhibits properties that are unique to the nanoscale. Here, the electrostatic and steric interactions between particle and surfaces become dominant in determining particle transport. At the solid-liquid interface of charged surfaces an electric double layer (EDL) forms due to electrostatic interactions between surfaces and charged particles. In these systems, tunable charge-selective nanochannels can be generated by manipulating electrostatic gating via co-ions exclusion and counterions enrichment of the EDL at the solid-liquid interface. In this context, electrostatic gating has been used to modulate the selectivity of nanofluidic membranes for drug delivery, nanofluidic transistors, and FlowFET, among other applications. While an extensive body of literature investigating nanofluidic systems exists, there is a lack of a comprehensive analysis accounting for all major parameters involved in these systems. Here we performed an all-encompassing modeling investigation corroborated by experimental analysis to assess the influence of nanochannel size, electrolyte properties, surface chemistry, gate voltage, dielectric properties, and molecular charge and size on the exclusion and enrichment of charged analytes in nanochannels. We found that the leakage current in electrostatic gating, often overlooked, plays a dominant role in molecular exclusion. Importantly, by independently considering all ionic species, we found that counterions compete for EDL formation at the surface proximity, resulting in concentration distributions that are nearly impossible to predict with analytical models. Achieving a deeper understanding of these nanofluidic phenomena will help the development of innovative miniaturized systems for both medical and industrial applications.
Collapse
Affiliation(s)
- Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States
| | - Nevio Racca
- Department of Electronics and Telecommunications, Polytechnic of Turin, 10129 Turin, Italy
| | - Danilo Demarchi
- Department of Electronics and Telecommunications, Polytechnic of Turin, 10129 Turin, Italy
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States
- Department of Surgery, Houston Methodist Research Institute, Houston, Texas 77030, United States
- Department of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas 77030, United States
| |
Collapse
|
3
|
Kumar G, Virmani T, Pathak K, Alhalmi A. A Revolutionary Blueprint for Mitigation of Hypertension via Nanoemulsion. BIOMED RESEARCH INTERNATIONAL 2022; 2022:4109874. [PMID: 35463984 PMCID: PMC9023159 DOI: 10.1155/2022/4109874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Accepted: 04/05/2022] [Indexed: 11/17/2022]
Abstract
Hypertension is one of the most important causes of mortality, affecting the health status of the patient. At the same time, hypertension causes a huge health and economic burden on the whole world. The incidence and prevalence of hypertension are rising even among young people in both urban as well as rural communities. Although various conventional therapeutic moieties are available for the management of hypertension, they have serious flaws such as hepatic metabolism, reduced dose frequency, poor aqueous solubility, reduced bioavailability, and increased adverse effects, making the drug therapy ineffective. Therefore, it is required to design a novel drug delivery system having the capability to solve the constraints associated with conventional treatment of hypertension. Nanotechnology is a new way of using and manipulating the matter at the molecular level, whose functional organization is measured in nanometers. The applications of nanotechnology in the field of medicine provide an alternative and novel direction for the treatment of cardiovascular diseases and show excellent performance in the field of targeted drug therapy. Various nanotechnologies based drug delivery systems, such as solid lipid nanoparticles, nanosuspension, nanoemulsion, liposome, self-emulsifying systems, and polymeric nanoparticles, are available. Among them, nanoemulsion has provided a niche to supplement currently available therapeutic choices due to numerous benefits like stability, ease of preparation, enhanced drug absorption, reduced hepatic metabolism, increased dose frequency, enhanced bioavailability, and encapsulation of hydrophilic as well as hydrophobic drugs. This present review provides an in-depth idea about progression in treatment of hypertension, constraints for antihypertensive drug therapy, need of nanoemulsions to overcome these constraints, comparative analysis of nanoemulsions over other nanostructure drug delivery systems, pharmacodynamics studies of nanoemulsions for treatment of hypertension, recent patents for drug-loaded nanoemulsions meant for hypertension, and marketed formulations of nanoemulsions for hypertension.
Collapse
Affiliation(s)
- Girish Kumar
- School of Pharmaceutical Sciences, MVN University, Haryana 121105, India
| | - Tarun Virmani
- School of Pharmaceutical Sciences, MVN University, Haryana 121105, India
| | - Kamla Pathak
- Uttar Pradesh University of Medical Sciences, Etawah, Uttar Pradesh 206001, India
| | - Abdulsalam Alhalmi
- Department of Pharmaceutics, College of Pharmacy, Aden University, Aden, Yemen
| |
Collapse
|
4
|
Yin L, Pang Y, Shan L, Gu J. The in vivo pharmacokinetics of block copolymers containing polyethylene glycol used in nanocarrier drug delivery systems. Drug Metab Dispos 2022; 50:827-836. [DOI: 10.1124/dmd.121.000568] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Accepted: 01/05/2022] [Indexed: 11/22/2022] Open
|